

# Public Health Committee JOINT FAVORABLE REPORT

**Bill No:** SB-451

AN ACT ESTABLISHING AN ADVISORY COUNCIL ON CHIMERIC ANTIGEN  
**Title:** RECEPTOR T-CELL THERAPY AND OTHER GENE THERAPIES.

**Vote Date:** 3/23/2026

**Vote Action:** Joint Favorable

**PH Date:** 3/13/2026

**File No.:** 566

***Disclaimer:** The following JOINT FAVORABLE Report is prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose.*

## **SPONSORS OF BILL:**

Public Health Committee

## **REASONS FOR BILL:**

Chimeric Antigen Receptor (CAR) T-cell therapy and other advanced gene therapies are for previously untreatable cancers as well as other diseases such as Sickle Cell Anemia, Type 1 diabetes, Lupus, and more. SB-451 creates a 28-member advisory council within the Department of Public Health (DPH) to advise and make recommendations to DPH and other state agencies regarding these therapies. The council will address (1) safe, equitable, and financially sustainable ways to deliver these therapies; (2) including referral and management protocols; and (3) advanced training for clinical providers.

The council may apply for and accept financing to fulfill its mission, as well as, enter contracts to distribute and use the funds. The council is required to report its findings and recommendations annually to the Insurance and Public Health Committees, with the first report due no later than one year after the date of the council's first meeting.

## **RESPONSE FROM ADMINISTRATION/AGENCY:**

None expressed.

## **NATURE AND SOURCES OF SUPPORT:**

### **Jodie Gillon, President & CEO, BioCT:**

Ms. Gillon describes SB 451 as "a thoughtful, forward-looking step toward improving access, safety, and health equity" for patients with previously untreatable cancers. CAR-T and other gene therapies "require significant coordination, specialized clinical training, and rigorous safety protocols," making the complexity and cost of providing such treatments increasingly

pressing. A statewide advisory council will serve as an important bridge between the legislature and important statewide stakeholders so that Connecticut remains a leader in advanced therapies. As innovative treatments progress, equitable access, workforce readiness, and safety oversight are urgent public health priorities.

**NATURE AND SOURCES OF OPPOSITION:**

None expressed.

**Reported by: Rebecca Hyland**

**Date: March 25, 2026**